Pulmonary Mucormycosis secondary to Severe Acute Respiratory Illness due to Covid 19 Infection: A Case Report

Authors

  • Ashish Karthak Department of Pulmonary, Critical care and Sleep Medicine, Nepal Mediciti Hospital, Nepal
  • Ashish Shrestha Department of Pulmonary, Critical care and Sleep Medicine, Nepal Mediciti Hospital, Nepal
  • Naresh Gurung Department of Pulmonary, Critical care and Sleep Medicine, Nepal Mediciti Hospital, Nepal
  • Yuvaraj Bhusal Department of Pulmonary, Critical care and Sleep Medicine, Nepal Mediciti Hospital, Nepal
  • Rakesh Lama Department of Pulmonary, Critical care and Sleep Medicine, Nepal Mediciti Hospital, Nepal
  • Sulav Rayamajhi Department of Pulmonary, Critical care and Sleep Medicine, Nepal Mediciti Hospital, Nepal
  • Sanjeet Bhattarai Department of Pulmonary, Critical care and Sleep Medicine, Nepal Mediciti Hospital, Nepal
  • Asim Regmi Department of Critical care Medicine, Nepal Mediciti Hospital, Nepal
  • Anup Ghimire Department of Critical care Medicine, Nepal Mediciti Hospital, Nepal
  • Kishor Khanal Department of Critical care Medicine, Nepal Mediciti Hospital, Nepal
  • Sanjeet K Shrestha Department of Pulmonary, Critical care and Sleep Medicine, Nepal Mediciti Hospital, Nepal

DOI:

https://doi.org/10.3126/nrj.v1i1.45235

Keywords:

Pulmonary mucormycosis, Severe acute respiratory illness, Mortality

Abstract

Patients diagnosed and hospitalized with SARS COV-2 are managed with corticosteroids due to its known benefits for the prevention of airway inflammation secondary to acute respiratory distress syndrome seen commonly in viral pneumonia. However, these patients carry a high risk of developing secondary bacterial and fungal infection. We present a case of 60-year-old male with COVID-19 pneumonia. The patient was diagnosed with pulmonary mucormycosis 18 days following admission. The patient was treated with broad-spectrum antibiotics, remdesivir and corticosteroids along with antifungals including voriconazole and amphotericin B with no significant improvement. However, even after extensive medical management patient was eventually intubated and succumbed to its complications. Mucormycosis although an uncommon infection should be considered due to extensive use of glucocorticoid therapy and concurrent comorbidities present among COVID-19 patients.

Downloads

Download data is not yet available.
Abstract
152
PDF
109

Downloads

Published

2022-05-23

How to Cite

Karthak, A., Shrestha, A., Gurung, N., Bhusal, Y., Lama, R., Rayamajhi, S., Bhattarai, S., Regmi, A., Ghimire, A., Khanal, K., & Shrestha, S. K. (2022). Pulmonary Mucormycosis secondary to Severe Acute Respiratory Illness due to Covid 19 Infection: A Case Report. Nepalese Respiratory Journal, 1(1), 15–18. https://doi.org/10.3126/nrj.v1i1.45235

Issue

Section

Case Reports